Send to

Choose Destination

See 1 citation found by title matching your search:

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00539-17. doi: 10.1128/AAC.00539-17. Print 2017 Jul.

Anti-influenza Activity of a Bacillus subtilis Probiotic Strain.

Author information

Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Sciences of Ukraine, Kiev, Ukraine.
Institute of Microbiology and Virology, National Academy of Sciences, Kiev, Ukraine.
Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, Alabama, USA


Among Bacillus bacteria, B. subtilis is the species that produces the most antimicrobial compounds. In this study, we analyzed the activity of probiotic strain B. subtilis 3 against the influenza virus. The antiviral effect of this strain has been demonstrated in vitro and in vivo A new peptide, P18, produced by the probiotic strain was isolated, purified, chemically synthesized, and characterized. Cytotoxicity studies demonstrated no toxic effect of P18 on Madin-Darby canine kidney (MDCK) cells, even at the highest concentration tested (100 μg/ml). Complete inhibition of the influenza virus in vitro was observed at concentrations of 12.5 to 100 μg/ml. The protective effect of P18 in mice was comparable to that of oseltamivir phosphate (Tamiflu). Further study will assess the potential of peptide P18 as an antiviral compound and as a promising candidate for the development of new antiviral vaccines.


Bacillus subtilis; antiviral peptide; influenza virus; probiotics

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center